Siegall Clay B reported option exercise involving 128,054 derivative units of Shattuck Labs, Inc. on May 22, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed May 27, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
128,054Warrants (Right to Buy)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
May 22, 2026Option exercise
Filed
May 27, 2026, 6:05 AM ET5-day reporting delay
Accession
0001193125-26-240347Code M · Transaction 87292
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Grant128,054$1.08$138,887.37Trade 87291
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

STTK price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
STTK · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +28%1w ago +3.3%1d ago +0.5%
Returns since7d −22%30d +6.3%90d +32%180d1y

Footnotes in full

F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.